Lymph node metastases (pN1) at prostatectomy are infrequent but impact prognosis. Traditional prostate nomograms assess age, serum prostatic-specific antigen (PSA), clinical stage, and biopsy parameters to inform decisions on pelvic lymph node dissection. The impact of intraductal carcinoma (IDC) and cribriform pattern 4 (CC) on nodal metastases has yet to be explored. (Source: European Journal of Cancer)
Our study demonstrates a high rate of nosocomial transmission of COVID-19, associated with increased mortality in both univariate and multivariate analysis in the cancer population, reinforcing the importance of treating patients with cancer in COVID-free units. We also validated that age and advanced cancer were negative predictive factors for COVID-19 severity in patients with cancer. (Source: European Journal of Cancer)
In the field of medical oncology, targeted therapies have greatly improved the prognosis of patients but renal side-effects have progressively emerged, leading to drug withdrawal that may negatively impact optimal therapeutic management and oncological outcome [1]. (Source: European Journal of Cancer)
Background: While generally ER IHC positive breast cancer patients receive endocrine treatment, not all of them respond. A test to predict therapy response with higher specificity is needed to avoid endocrine overtreatment and to consider alternative therapies. To this end, we developed computational models to assess functional activity of signal transduction pathways (Verhaegh et al., Cancer Res 2014; Inda et al, Mol Cancer Ther 2019), based on interpreting mRNA expression levels of the respective...
Background: Several studies have shown that Neutrophil to lymphocyte ratio (NLR) is an unfavorable prognostic factor for many cancers including early breast cancer. Some studies also suggest that NLR may predict the efficacy of chemotherapy. The aim of this study is to examine the relationship between NLR and efficacy of Eribulin treatment. (Source: European Journal of Cancer)
Data regarding real-world impact on cancer clinical research during COVID-19 are scarce. We analysed the impact of the COVID-19 pandemic on the conduct of paediatric cancer phase I-II trials in Europe through the experience of the Innovative Therapies for Children with Cancer (ITCC). (Source: European Journal of Cancer)
Radiotherapy and cisplatin-based combination chemotherapy are accepted standard-of-care treatments for metastatic seminoma with excellent survival outcomes but with established short- and long-term morbidity. Carboplatin monotherapy may be a less toxic alternative; however early historic studies at AUC7 showed inferior outcomes. (Source: European Journal of Cancer)
Cancer patients are thought to have an increased risk of developing severe Coronavirus Disease 2019 (COVID-19) infection and of dying from the disease. In this work, predictive factors for COVID-19 severity and mortality in cancer patients were investigated. (Source: European Journal of Cancer)
Patients with cancer might have an increased risk for severe outcome of coronavirus disease 2019 (COVID-19). To identify risk factors associated with a worse outcome of COVID-19, a nationwide registry was developed for patients with cancer and COVID-19. (Source: European Journal of Cancer)
A Systematic Review and Meta-Analysis: The Effect of Active Cancer Treatment on Severity of COVID-19
In this study, we assessed the effect of cancer treatment on the severity of COVID-19. (Source: European Journal of Cancer)
Optimal dosing of bone-targeted agents (BTAs), in patients with bone metastases remains an important clinical question. This trial compared 4-weekly versus 12-weekly therapy. (Source: European Journal of Cancer)
We appreciate the interest and comments provided on our publication on contemporary outcomes of patients with metastatic breast cancer (MBC) [1] by Dr. M.K. Fink. (Source: European Journal of Cancer)
Adjuvant therapy is the decisive reason why the cure rate of breast cancer increased in the last decades. However, it cures only tumours that are sensitive to this treatment. Relapsing tumours are unavoidably the high risk selection, and their presumptive resistance is further strengthened by the ineffective adjuvant therapy. Therefore postmetastatic survival after an adjuvant therapy is reduced. Rowan Chlebowski described this effect already in 1986 [2] when comparing an adjuvant treatment with...
Background: The benefits and harms of breast cancer screening programmes have been debated. Recent improvements in treatment as well as changes in screening performance may shift the balance between benefits and harms and might imply that current strategies may not be the most optimal. In addition, some countries are facing capacity issues. Therefore, this cost-effectiveness study evaluates optimal screening intervals in the Netherlands. (Source: European Journal of Cancer)
Triple negative (TN) breast cancer (BC) is an uncommon and aggressive subtype of BC associated with early disease recurrence and short survival. In literature, prevalence of BRCA mutations in TNBC patients may vary from 9 to 32%. The prevalence of BRCA germline mutations has been systematically evaluated in this setting of patients at our center. (Source: European Journal of Cancer)
Introduction: In November 2019 the Royal College of Radiologists (RCR) suggested that a higher age cut-off of 30 years, as opposed to 25, may be appropriate in assessment of a lump when a fibroadenoma, lipoma or hamartoma is suspected, and a needle biopsy may not be required. We assessed whether this change in practice could be safely implemented, supported by local data and if we could adopt this in a multi-ethnic inner-city population. (Source: European Journal of Cancer)
Introduction: Breast and ovarian cancer account for approximately 15000 deaths per year in the United Kingdom. It is estimated that up to 20% of these cases have an inherited genetic aetiology. The most common genetic mutation occurs in the BRCA1 or 2 genes. For women with mutations in these genes, or a high incidence of breast and/or ovarian cancer in their family, riskreducing bilateral salpingo-oophorectomy (RRBSO) may be offered to eliminate the risk of primary ovarian cancer. In pre-menopausal...
Background: PreCycle (NCT03220178) is a multicenter, randomized phase IV Intergroup trial to evaluate the impact of eHealth-based Patient-Reported Outcome (PRO) assessment on quality of life (QoL) in patients with HR +/HER2 − locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant. Patients willing to use the web/APP-eHealth solution CANKADO were eligible. Patients were randomized (2:1) to the active or inform arm (and stratified...
This study aims to describe exposure of the oesophagus from modern breast cancer regimens. (Source: European Journal of Cancer)
Background: Triple-negative breast cancer (TNBC) is a kind of breast cancer with early recurrence and high heterogeneity, lacking targeted therapies. TNBC possessed few mutations but many somatic copy number alterations (SCNAs). (Source: European Journal of Cancer)
In this study, we investigated the relationship between BAT activity detected by FDG-PET and immunological factors, including degrees of tumor-infiltrating lymphocytes (TILs), and programmed cell death ligand 1 (PD-L1), which have been suggested as prognostic factor in BC. (Source: European Journal of Cancer)
Background: Invasive lobular breast cancer is the second most common breast cancer (BC) subtype. Clinicopathological parameters associated with lobular BC and their prognostic implications are still controversial. (Source: European Journal of Cancer)
Background: Upfront surgery is the gold standard of treatment for early-stage breast cancer (EBC) in fit older women. It reduces the risk of local recurrence and the associated morbidity and has a positive impact on overall survival. However, primary endocrine treatment is commonly used for older women with co-morbidities that are considered medically unfit for surgery. We aim to present data for older women treated with endocrine therapy alone. (Source: European Journal of Cancer)
Background: Early age at onset of breast cancer is a known risk factor for hereditary predisposition. The likelihood of BRCA1, BRCA2 and TP53 pathogenic variants (PVs) increases with earlier age at diagnosis, but little is known about the age distribution of PVs in other predisposition genes. Here, we assessed the contribution of known breast cancer-associated genes to very early onset disease. (Source: European Journal of Cancer)
Background: There has been a global trend for surgical de-escalation in the management of breast cancer. There has been widespread acceptance that ‘no tumour at ink’ is adequate following breast conservation surgery (BCS) for invasive malignancy and also that completion axillary clearance (cANC) is not required in all women with a positive sentinel node biopsy (SLNB). UK National Guidelines for surgical margins and axillary management were updated in 2018 to reduce axillary completion clearance indications...
Background: Fatigue is the most common and persistent symptom among women in the first five years after a breast cancer diagnosis. To compare fatigue experienced by long-term breast cancer survivors with that in a reference population, and to evaluate the determinants of that fatigue. (Source: European Journal of Cancer)
Introduction: Specific prognostic scores for patients with breast cancer (BC) brain metastases and/or leptomeningeal carcinomatosis (LMC) can help predict expected survival in order to choose the most appropriate treatment. The aim of this study was to perform a validation of recently published prognostic survival indexes, namely Breast Graded Prognostic Assessment (Breast-GPA), Simple Survival Score for Brain Metastases (SS-BM) and Index score. (Source: European Journal of Cancer)
Background: Women with ≥20% lifetime risk for breast cancer because of their family history, but without a BRCA1/2 mutation are advised to have screening with yearly MRI in the USA, but with mammography in Europe. We recently published in Lancet Oncology how much earlier MRI screening can detect the breast cancers compa red with mammography, but at the cost of more false-positive results, in a randomized trial in twelve Dutch hospitals. (Source: European Journal of Cancer)
Background: Hepatocyte growth factor receptor (HGFR) or c-Met and vascular endothelial growth factor receptor (VEGFR) are protein kinase receptors that once binds to their ligands, hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF), respectively, augment cell proliferation, invasiveness and scattering, resulting in tumor progression and angiogenesis in a broad spectrum of cancers. Intensified HGF/c-met signaling is also a well-known mechanism of resistance to VEGFR-TKIs...
Background: Breast cancer (BC) screening can be performed in a screening program (BCSP) or an opportunistic screening. The existing reviews on determinants associated with the non-participation in BC screening including self-reported screening non-participation and studies from the two screening strategies were combined in these reviews. To find determinants associated with the non-participation in BCSP with meta-analyses. (Source: European Journal of Cancer)
Background: Paclitaxel, Docetaxel and Vinorelbine exert anti-tumor activity by interfering with microtubule dynamics, leading to mitotic arrest. Though these agents are commonly used in treatment of breast cancers, therapy failures are noted due to innate and acquired chemoresistance. Real-time monitoring of chemoresistance towards such treatment agents is an unmet clinical need since conventional methods for chemoresistance profiling (CRP) necessitate invasive biopsies to obtain viable tumor tissue....
Background: None of the key randomized trials on the omission of axillary lymph node dissection (ALND) in sentinel lymph node (SLN)-positive breast cancer have reported external validity, though results indicate selection bias. Our aim was to assess the external validity of the ongoing randomised SENOMAC trial by comparing characteristics of Swedish SENOMAC trial participants with non-included eligible patients registered in the Swedish National Breast Cancer Register (NKBC). (Source: European Journal...
Background: The family history clinic started offering Tamoxifen as a riskreducing measure in 2015 in line with the NICE clinical guidance on Familial breast cancer. In 2017, following an amendment to the guidance, postmenopausal patients were also offered Anastrazole. (Source: European Journal of Cancer)
Background: The therapeutic role of completion axillary dissection (ALND) has been increasingly questioned in breast cancer patients with limited axillary lymph node metastases. Several studies have suggested non-inferior axillary recurrence and survival rates in patients with or without completion ALND. Patients undergoing mastectomy, however, are underrepresented, and there are indications of selection bias in key trials. (Source: European Journal of Cancer)
Background: Stereotactic VAB is the gold standard in the biopsy guidance of nonpalpable breast lesions which cannot be detected on ultrasound. The aim of this study is to learn about prone, stereotactic, vacuum-assisted core biopsy (PS VAB) systems through our experience: (Source: European Journal of Cancer)
Background: More than one-third of clinically node positive (cN+) breast cancer (BC) patients currently show a pathologic complete response (pCR) of the axilla after neoadjuvant systemic therapy (NST). In patients with pCR, axillary lymph node dissection (ALND) is considered as overtreatment. The MARI procedure (Marking Axillary lymph nodes with Radioactive Iodine seeds) combined with pre-NST FDG-PET/CT (MARI protocol) is an accurate method to restage the axilla after NST. Here, we present 3-year...
Background: Recent advances in the understanding of malignant diseases have shown that some tumorigenic genomic alterations associated with the hallmarks of cancer can be therapeutically addressed by molecularly targeted agents. Comprehensive genomic profiling identifying such actionable alterations aims to offer personalized treatment to cancer patients. With the ongoing approval of many targeted therapies, the growing field of precision medicine is constantly expanding and requires optimization....
Background: Fragmented DNA is constantly released into the circulation by apoptosis and necrosis of both cancerous and non-cancerous cell. When it is released by cancer cells, it is specifically known as circulating tumour DNA (ctDNA). We performed a systematic review and meta-analysis to determine the clinical utility of ctDNA as a prognostic biomarker in predicting breast cancer outcomes. (Source: European Journal of Cancer)
Background: Real-world data help identify current medical needs, and inform future therapeutic developments. We aimed to describe the full characteristics and outcomes in the ESME cohort, a large national contemporary observational database of patients with metastatic breast cancer (MBC). (Source: European Journal of Cancer)
Background: Breast conservation (BCS) is the standard surgical procedure for early breast cancer. It is a challenge for surgeons to achieve adequate excision of lesion with clear margins and acceptable cosmesis. To remove precisely the volume of tissue required, continuous intra-operative ultrasound (IOUS) had been used during BCS. We reviewed its effectiveness to obtain clear margins, low excision volume and better cosmetic outcome. (Source: European Journal of Cancer)
Background: During three last decades, the breast cancer (BC) landscape has changed considerably e.g. due to early-detection by screening and the more widespread use of (neo) adjuvant systemic treatments. The effects of these developments have influence on stage and treatment management, and trends in core epidemiological indicators and clinical management have hardly been studied. The aim of this study was to provide a comprehensive overview of the trends in incidence, mortality, survival and treatment...
Chemotherapy and particularly radiotherapy result in adverse cutaneous effects in breast cancer patients, leading to a clinical burden comprising chronic skin lesions and healing impairment, reducing the quality of life of these individuals. (Source: European Journal of Cancer)
Background: Chemotherapy-treatment (CT) decision for patients (pts) diagnosed with Invasive Lobular Carcinoma (ILC) remains controversial. We investigated the clinical utility of MammaPrint in pts diagnosed with early-stage ILC enrolled in MINDACT. (Source: European Journal of Cancer)
The objective of this study was to evaluate, based on a retrospective monocentric cohort of breast cancer patients treated before 20 15, the clinical impact of the use of an Artificial Intelligence (AI)-based solution for organs-at-risk (OAR) and target volume delineation, respecting international guidelines. (Source: European Journal of Cancer)
Background: (Neo) adjuvant treatments including anthracyclines, trastuzumab and (left-sided) radiotherapy (RT) are associated with an increased risk of cardiovascular disease (CVD). Breast cancer patients with pre-existing CVD risk factors have the highest risk of treatment induced cardiotoxicity. Coronary artery calcium (CAC) is a strong independent CVD risk factor and can be quantified on dedicated radiotherapy planning CT scans of the chest. Automated assessment of CAC scores in breast cancer...
Background: Guidewires for a long time represented the standard localisation method for impalpable lesions prior to breast conserving surgery but alternative methods are now available. (Source: European Journal of Cancer)
Background: In breast cancer (BC) management, age related practice variance is widespread with older women having lower rates of surgery, based on the premise of poor tolerance and reduced treatment benefit. Primary endocrine therapy (PET) may be appropriate in those who are unfit for surgery or with a limited life expectancy. This prospective multi-center study aimed to determine co-morbidity and frailty thresholds beyond which surgery is no longer beneficial. (Source: European Journal of Cancer)
Background: Neoadjuvant endocrine treatment (NET) is increasingly used in early stage ER positive breast cancer (EBC) mainly in post-menopausal patients. This approach shows response rates (RR) comparable to neoadjuvant chemotherapy for some patients but randomised trials are limited. We set out to review the RR in patients treated with NET at our UK centre. (Source: European Journal of Cancer)
Introduction: Breast cancer (BC) survival in older women is inferior to younger women partly due to reduced rates of surgery, chemotherapy and radiotherapy. Some treatment variance may be appropriate to minimise complications in the least fit older women, but there are no guidelines to aid decision-making regarding the level of fitness where such tailored approaches are appropriate. This cluster-randomised controlled trial (cRCT) has evaluated the impact of two decision support tools (DESIs) in older...
Introduction: Current guidelines recommend the use of hormone therapy plus CDK 4/6 inhibitors (CDK4/6i) as initial treatments in patients (pts) with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer (ABC). The subgroup analyses of phase III studies of CDK4/6i did not identify any predictive marker that could help the clinicians to address the therapeutic choice. (Source: European Journal of Cancer)
Background: In PALOMA-3, endocrine therapy (ET)-sensitive (ie, documented clinical benefit from prior ET or 2 y adjuvant ET before recurrence) pts with HR+/HER2 – ABC and disease progression on prior ET derived overall survival (OS) benefit from palbociclib (PAL) + fulvestrant (FUL) vs placebo (PBO)+FUL. In pts who received prior chemotherapy (CT) for ABC, median (m)OS was similar between treatment arms, suggesting that prior CT impacts the benefit of PAL +FUL. This post hoc analysis reports OS and...
Background: Accurately measuring tumor size is challenging in invasive lobular carcinoma (ILC), which shows non-cohesive growth due to its lack of the adhesion protein E-cadherin. In the metastatic setting, ILC has a unique pattern of spread with a tendency to involve organs like the gastrointestinal tract, peritoneal lining, leptomeninges, or pleura. This results in sheet-like disease or effusions that cannot be measured on routine imaging tests, with measurable disease developing later in the disease...
This study examined the uptake of chemoprevention by Australian women at increased risk and aimed to identify modifiable barriers and facilitators for both patients and clinicians. (Source: European Journal of Cancer)
Background: Cancer patient outcome depends on a variety of different factors including tumor histology, genetic factors, and response to first-line treatment. In the era of personalized medicine, the ability of pre-selecting individualized treatment options and pre-defining their suitability in advance of clinical treatment, might facilitate therapeutic decision making and finally improve patient outcome. However, for preclinical validation of anti-cancer drug efficacy, it is crucial to design a...
Background: Studies have shown that screen-detection by national screening programs is independently associated with better prognosis of breast cancer. This association can not only be explained by clinical-pathological prognostic factors. Previously, we showed there was a significantly higher proportion of breast cancers with a high risk tumor biology according to the 70-gene signature (70-GS) among interval cancers compared to screen-detected cancers. The aim of this study is to evaluate the association...
Background: One of the main advantages of neoadjuvant chemotherapy (NACT) for breast cancer (BC) is an early initiation of systemic control of disease. However, the effectiveness of NACT does not correlate with the result of standard micro-morphological regression (RG) analysis, thus disease is in some cases not well controlled or even progressed. The main aim was to categorize the micro-morphological markers of RG and the baseline characteristics of tumor that identify patients at high risk of NACT...
Background: Improvements in neoadjuvant systemic therapy (NST) for breast cancer (BC) patients have led to increasing rates of pathologic complete response (pCR). In patients with an excellent response, imaging alone is not accurate enough to identify patients with pCR, in whom surgery could be considered overtreatment. In the MICRA trial (NTR6120) a combination of MRI and minimal invasive biopsies of the breast is used to identify patients with pCR after NST. (Source: European Journal of Cancer)
High-throughput 16S rRNA sequencing (HTS) has recently been used to describe the microbial communities of in-vivo compartments that were up until that point described as “sterile.” Among these is the human breast, the microbiome of which was described by our group in patients with and without breast cancer. The impression of the healthy and malignant mammary microbiome to date has been informed primarily by 16S metabarcoding data, and only sparingly by culture-b ased assays, which may lead to an...
Background: Implant-based breast reconstruction (IBBR) after mastectomy either with TE or DTI in pre-pectoral position has been widely accepted. The pre-pec breast reconstruction, in fact, spares muscles, preserving the natural anatomy and reduces post-operative pain. Moreover, the pre-pec approach is associated to a decreased risk of capsular contracture and animation deformities. An increasing number of women, who undergo IBBR, will require post mastectomy radiotherapy (PMRT), since the meta-analysis...
Introduction: Carriers of the BRCA 1 and/or BRCA 2 mutation incur a lifetime risk of up to 85% for breast cancer and between 20 and 40% for ovarian cancer. Efforts to elucidate the lifetime risk of developing colorectal cancer with BRCA carrier mutations have demonstrated conflicting results. Consequently, there are no formal guidelines regarding the necessity for bowel screening for individuals with BRCA 1 and/or BRCA 2 mutations. A systematic review and meta-analysis was performed to determine...
This study aimed to assess the long-term risk of ipsilateral subsequent in situ and invasive lesions after a diagnosis of primary DCIS and the association with initial DCIS treatment. (Source: European Journal of Cancer)
In this study we assessed whether muscle quality as expressed by skeletal muscle radiodensity (SMD) and relative muscle volume as expressed by skeletal muscle indexes (SMI) are independent prognostic risk factors for postoperative complications in women undergoing DIEP-flap breast reconstruction (BR). (Source: European Journal of Cancer)
Background: Benign breast diseases (BBD) are related with an increased risk of developing breast cancer and have been proposed as a risk factor to personalize breast cancer screening strategies. This risk varies significantly depending on the pathological characteristics of the BBD. Our aim was to explore the differences in the risk of breast cancer across BBD types diagnosed at prevalent or incident screen in a population-based mammography program. (Source: European Journal of Cancer)
Background: Clinical significance and treatment value of detection of isolated tumor cells (pN0(i+) = 0.2 mm and below) or micrometastasis (pN1mi = 0.2 –2 mm) in sentinel lymph node biopsy (SLNB) in early-stage breast cancer is still controversial. Randomized studies have shown that advanced axillary lymph node dissection (ALND) need not be performed. However, radiotherapy (RT) fields that should be irradiated are not clear. In our study, advance d axillary treatments (dissection or RT) were evaluated...
Background: Survival rates for breast cancer (BC) are increasing due to improved surgery and multimodality oncological treatment, leading to growing interest in treatment-related late-effects (LEs). The aim of the present study was to explore LEs using Patient-Reported Outcome Measures in postmenopausal BC survivors in standard follow-up care. The results were compared to age- and gender-matched data from the general Danish population. (Source: European Journal of Cancer)
Background: Ductal carcinoma in situ (DCIS) identified by screening mammography accounts for 20% of breast cancer diagnoses, and microinvasion (DCIS-M) is found in 5% –10%. There are no defined treatment guidelines for palpable DCIS or DCIS-M. The role of screening mammography is now being questioned across the world and in the developing world with no national screening programs, women with DCIS present with a palpable lump in the breast. We conducted a retros pective audit of women with DCIS treated...
Background: The cumulative incidence of invasive contralateral breast cancer (CBC) for patients with first invasive breast cancer (BC) is approximately 0.4% per year. Less is known about CBC risk in patients with ductal carcinoma in situ (DCIS). We aimed to assess the CBC risk in patients with first DCIS compared to those with invasive BC, taking age, screening period, and (neo) adjuvant systemic therapy into account. (Source: European Journal of Cancer)
This study was designed to identify common single nucleotide polymorphisms (SNPs) associated with acute radiation toxicity and change in QoL on completion of radiotherapy. (Source: European Journal of Cancer)
Background: Use of OCAM varies widely among cancer pts, ranging 20 – 80%. Efficacy of OCAM for cancer-related symptoms including fatigue is controversial, while some interactions with standard anticancer therapy were reported. We aimed to describe factors associated with use of OCAM, particularly its relationship with self-reported fatigue in BC pts. (Source: European Journal of Cancer)
Background: Predicting the risk of recurrence of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative invasive breast cancer is crucial for deciding on adjuvant treatment. Several multigene tests are nowadays commercially available for predicting the risk of recurrence and avoiding overtreatment. Although some of these tests are recommended in national guidelines, there are still unanswered questions about their utility and cost-effectiveness. The European Commission...
This study aims to be the first to explore if concomitant DCIS affects the clinical behavior in terms of disease progression and overall survival among Asian patients with IDC. (Source: European Journal of Cancer)
We examined how breast cancer risk factors are associated with MD area (cm2) change across age. (Source: European Journal of Cancer)
Background: Breast cancer screening has always been a challenging task in underdeveloped countries like Pakistan. We believe that during this era precision medicine for breast cancer is the most accurate approach in prevention, diagnosis and treatment of the disease. Several kinds of genetic and nongenetic tests for breast cancer are available that can help personalised therapy. Our study aims to find the role of precision medicine in breast cancer screening. (Source: European Journal of Cancer)
Background: Radiomics is the extraction and analysis of quantitative imaging features that are beyond the perception of the human eye and has been shown to improve diagnostic accuracy. To date radiomics coupled with machine learning (ML) has been mainly applied to dynamic contrast-enhanced MRI (DCE-MRI) but mining quantitative radiomics features extracted from DWI may further improve diagnostic accuracy. We evaluated radiomics and ML with DWI for breast cancer diagnosis and compared diagnostic accuracy...
Background: Metastatic breast cancer remains a treatable, yet incurable disease. These patients have different healthcare requirements to patients with early breast cancer due to unique disease characteristics and outcomes. The information provided to them must be tailored accordingly. This review will aim to analyse the demographics, survival and disease characteristics of those diagnosed with metastatic breast cancer and further compare recurrent to de novo metastatic disease. (Source: European...
Background: The 70-gene signature MammaPrint ® has been shown to identify breast cancer patients for whom adjuvant chemotherapy (CT) could be considered to be omitted even in the presence of unfavorable standard clinical-pathological criteria. In 2016 the MINDACT trial showed excellent 5-year distant metastasis-free survival of 94.7% (95%CI 9 2.5–96.2) in clinical high (C-High)/genomic low (G-Low) risk patients who did not receive chemotherapy. Long-term follow-up is now presented. (Source: European...
Background: Hormone positive, HER-2 negative metastatic breast cancer (HR+/HER2- MBC) had always been challenging to treat. With the addition of Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors to the treatment armamentarium, these patients have not only shown improvement in progression free survival (PFS) and response rates (RR) but also overall survival (OS) has improved in both the lines compared with endocrine therapy (ET) alone. Since 2017, in India, the combination of CDK4/6 inhibitors with...
Background: Single nucleotide polymorphisms (SNPs) have been reported some of which increase or decrease the risk of breast cancer. However, few studies have investigated the association of SNPs and hot flushes in women taking preventive endocrine therapy for breast cancer. Here, we investigate whether SNPs are associated with hot flushes and whether multiple SNPs can be used to predict hot flush occurrence in the first International Breast Intervention Study (IBIS-I). (Source: European Journal of...
Background: Population-based cancer registries (CRs) collect data that enable computation of cancer incidence in a well-defined area. Moreover, most registries collect more extensive information such as data on stage and treatment (in particular first course of anticancer therapy), which can be used to assess and compare different care pathways. The current analysis reports on treatment by stage patterns for female breast cancer in Europe. (Source: European Journal of Cancer)
Background: Lapatinib (L) plus trastuzumab (T) with weekly paclitaxel significantly increased the pathologic complete response (pCR) rate (51.3%) compared with either anti-human epidermal growth factor receptor 2 (HER2) drug alone (24.7%% for L, 29.5% for T). Here, we report the results of the prespecified long-term event-free survival (EFS) and overall survival (OS) analyses by the treatment arms. In addition, we assess the relationship between pCR and survival, both in the overall study population...
Background: As older patients with breast cancer are often not included in clinical trials, we currently have a limited number of specific recommendations available for their management. In this paper, we are presenting a single-center study describing the influence of older age on breast cancer treatment and prognosis. (Source: European Journal of Cancer)
This study aimed to estimate the effects of four restart strategies after the disruption on screening capacity and cancer burden. (Source: European Journal of Cancer)
Background: Aromatase inhibitors (AI ’s) are the gold standard adjuvant treatment for post-menopausal women with oestrogen-receptor positive breast cancer (BC) but accelerate bone loss and increase fracture risk. (Source: European Journal of Cancer)
Background: The recent COVID-19 pandemic has caused profound changes on the health-care systems as well as deleterious repercussions on the care of patients with cancer. In this comparative study, we sought to evaluate the effects the COVID-19 pandemic on the surgical management of breast cancer in a Breast Unit belonging to an Italian region with a low incidence of COVID-19 infection. (Source: European Journal of Cancer)
Background: A failure of sentinel lymph node (SLN) mapping during sentinel lymph node biopsy (SLNB) is usually an indication for axillary lymph node dissection (ALND) usually involving dissection of axillary lymph nodes in the level I. However, according to recommendations of some scientific associations, it is not always necessary. This proves that significant differences still exist, when optimum management is concerned in the event of a failure of SLN identification. (Source: European Journal...
Background: The COVID-19 pandemic, and the resulting measures, are impacting daily life and medical management of patients with breast cancer. We evaluated to what extent these changes have affected quality of life, and physical and psychosocial wellbeing of patients (being) treated for breast cancer. (Source: European Journal of Cancer)
Background: In breast conserving surgery accurate intraoperative lesion localization is essential for adequate surgical margins while sparing surrounding healthy tissue to achieve optimal cosmesis. Radiofrequency identification (RFID) technology may offer a viable non-radioactive, non-wire alternative. (Source: European Journal of Cancer)
Background: Saliva is an easily accessible and informative biological fluid which has high potential for the early diagnosis of various diseases. The primary aim of this study is to develop machine learning methods and to explore new salivary biomarkers to discriminate breast cancer patients from healthy controls. The secondary aim of this study is to evaluate the possibility of breast cancer subtype diagnosis by salivary metabolomics analysis. (Source: European Journal of Cancer)
No conflict of interest. (Source: European Journal of Cancer)
Background: Breast cancer and its treatments affect patients ’ health-related quality of life (HRQoL) both during therapy and afterwards. Variation among patients in QoL is clinically significant but the sources thereof only partially known and thereby challenging to predict. (Source: European Journal of Cancer)
Background: Advanced cancer stage is detrimental to patients ’ quality of life (QOL), and should be mostly handled using palliative care (PC) strategies. Understanding factors that influence QOL of cancer patients in PC units in developing countries is necessary, but this information is limited. Therefore, this systematic review aims to summarize the eviden ce on this topic. (Source: European Journal of Cancer)
This study explores the impact of mesh use on the 18-month PROs of IBBR in the iBRA cohort. (Source: European Journal of Cancer)
Background: Brain metastases (BM) have become a major challenge in the management of patients with metastatic breast cancer. So far, it is unclear whether an earlier detection of BM is associated with a better prognosis. (Source: European Journal of Cancer)
Background: The cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) represented the standard I-II lines of hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2 −) metastatic breast cancer (MBC). Data regarding toxicity safety profiles when combining CDK4/6i with palliative radiotherapy (RT) are still lacking. RT use with palliative and ablative intents is currently increasing due to promising results in the oligometastatic setting. We aim to investigate acute...
Background: Due to the common exclusion of older patients with cancer from clinical trials, few specific data are available on the treatment of advanced breast cancer (ABC) in this population. (Source: European Journal of Cancer)
Background: Notwithstanding the encouraging results seen with everolimus in advanced breast cancer, reliable biomarkers of response to mTOR inhibitors are yet to be identified. As mTOR is heavily implicated in cell-metabolism, we investigated the relation between BMI variation and outcomes in metastatic breast cancer (mBC) patients treated with everolimus. (Source: European Journal of Cancer)
Background: The composition and function of the gut microbiome may influence the activity of systemic anti-cancer therapies. However, it is not yet known whether and how the gut microbiome impacts on chemo-sensitivity in breast cancer. To address this we have investigated associations between short chain fatty acids (SCFAs), key functional metabolites of the gut microbiome, and pCR. (Source: European Journal of Cancer)
Breast cancer (BC) incidence is on the rise in India. Early detection is limited due to lack of awareness in women about disease symptoms, screening modalities, breast self-examination and/or routine mammographic screening leading to negligence and costly delay in diagnosis and treatment. (Source: European Journal of Cancer)
Background: Breast cancer surgery has undergone dramatic paradigm shift from radical mastectomy to conservation surgery due to increased awareness and hence, early diagnosis. There has been an increasing acceptance of contralateral prophylactic mastectomy in the Western world which is slowly gaining popularity in the Asian society for fear of developing metachronous breast cancer. In Southeast Asia, the prevalence of metachronous breast cancer has been assumed to be low and non-hereditary though...
FEEDS YOU MIGHT LIKE
Background: Recently, our research group has highlighted the potential ability of the natural compound, 3 ′-O-acetylvitexin, to modulate the oncogenic and the immunogenic profiles of TNBC cells. Yet, the exact molecular mechanism of such potential therapeutic agent has to be more extensively explored. Natural Killer cells (NKs) are the first invaders in the immune surveillance attack against TNBC. The major histocompatibility complex class I chain-related proteins A and B (MICA/B) are considered...
Background: Previously we reported that the survival rate of patients with the HER2 enriched breast cancer subtype who experienced recurrence after 2001 had improved with the availability of trastuzumab in Japan. Moreover, there is an increase in the variability of therapeutic agents for luminal or triple negative (TN) subtypes. The aim of this study is to demonstrate that there was a change in the recurrence rate and survival time of patients who received these new therapeutic agents after 2001,...
Background: Although mammographic screening for breast cancer (BC) has substantially increased the rates of detection of early-stage BC, a significant proportion of patients continues to be diagnosed in locally advanced or metastatic settings. The early BC diagnosis is of utmost importance for long-term survival, improving the quality of life and reducing costs for public healthcare. New BC screening approaches integrated with the radiological ones, could improve the early identification of BC, offering...
This study aims to analyze characteristics of IBTR after BCS in single center. (Source: European Journal of Cancer)
Background: New biomarkers are awaited to more accurately predict recurrence of luminal breast tumors and to decide whether or not adjuvant chemotherapy is indicated for these patients. Both the chemokine and microRNA networks have been implicated in the metastatic process. As chemokines and microRNAs are also present in the plasma, these could potentially hold interesting prognostic biomarker candidates. (Source: European Journal of Cancer)
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου